Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Phase 2 trial: Dendritic cell vaccine maintenance prolongs PFS in EOC
DCVAC maintenance after chemotherapy prolonged progression-free survival by almost 6 months in EOC patients who have undergone primary debulking...
News
Lower CTC count IDs indolent MBC disease subset
A CTC count less than 5 per 7.5 mL of blood in MBC patients indicates an indolent disease subset, pooled data from two large cohorts show.
News
Trial data suggest beneficial class effects of SGLT2 inhibitors, including dapagliflozin
ORLANDO – Data from EXSCEL placebo group subjects show beneficial class effects of SGLT2 inhibitors, including dapagliflozin, on MACE, ACM, and...
News
CVD-REAL 2: Lower mortality, CV risks with SGLT-2i vs. DPP-4i treatment in T2DM
ORLANDO – SGLT2 inhibitor treatment, compared with DPP-4 inhibitors, is associated with lower death, CV event, and stroke rates in patients with...
Video
RISE: Insulin glargine, metformin offer no beta cell function benefit in youth
ORLANDO – Findings from pediatric portions of RISE, a T2DM medication study, are disappointing but lay strong foundation for future studies in...
News
CANVAS data: Canagliflozin generally well tolerated up to 6.5 years
The longest-term safety data to date show that canagliflozin is generally well tolerated for up to 6.5 years in patients with T2DM and high CV...
News
CANVAS program analysis: Canagliflozin benefits patients with T2DM and poor kidney function
The cardioprotective benefits of canagliflozin in type 2 diabetes mellitus were similar across varying levels of kidney function in an analysis of...
Video
Intensive treatment for T2D pays off in the long run
ORLANDO – Long-term follow-up of the Steno-2 study confirms that intensive therapy for type 2 diabetes saves money because of reduced...
News
KEYNOTE-427: Pembrolizumab monotherapy shows promise in accRCC
CHICAGO – Pembrolizumab monotherapy shows promising efficacy and tolerability in treatment-naive patients with accRCC in the phase 2 KEYNOTE-427...
News
Average glucose, A1c discordance is common, highlights ADAG equation concerns
ORLANDO - Significant discordance exists between average glucose (AG) and HbA1c measures in patients on insulin, according to findings...
News
Blood and tissue TMB help predict checkpoint inhibition response in NSCLC
High bTMB and tTMB appear to have value as biomarkers for checkpoint inhibition response in patients with NSCLC, according to data presented at...